Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHA:603456)
China · Delayed Price · Currency is CNY 17.86
+0.20 (1.13%)
Feb 3, 2026, 2:55 PM CST
SHA:603456 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 5,282 | 5,086 | 5,406 | 5,181 | 3,823 | 2,487 |
Other Revenue | 74.24 | 74.24 | 117.58 | 264.29 | 240.52 | 160.74 |
| 5,356 | 5,161 | 5,523 | 5,445 | 4,063 | 2,647 | |
Revenue Growth (YoY) | 9.03% | -6.57% | 1.44% | 34.01% | 53.49% | 31.26% |
Cost of Revenue | 3,582 | 3,571 | 3,524 | 3,623 | 2,746 | 1,691 |
Gross Profit | 1,774 | 1,590 | 1,999 | 1,822 | 1,317 | 956.47 |
Selling, General & Admin | 504.23 | 513.31 | 524.15 | 480.09 | 383.42 | 340.13 |
Research & Development | 269.53 | 314.91 | 330.83 | 287.38 | 173.36 | 114.23 |
Other Operating Expenses | 52.87 | 29.47 | 21.97 | 34.67 | 26.52 | 29.07 |
Operating Expenses | 809.51 | 874.34 | 896.32 | 796.43 | 590.87 | 489.89 |
Operating Income | 964.58 | 715.31 | 1,103 | 1,026 | 725.97 | 466.58 |
Interest Expense | -8.85 | -19.38 | -21.73 | -22.38 | -24.87 | -43.55 |
Interest & Investment Income | 46.67 | 86.06 | 91.82 | 15.27 | 68.74 | 8.61 |
Currency Exchange Gain (Loss) | 12.52 | 12.52 | 9.02 | 97.03 | -18.36 | -50.73 |
Other Non Operating Income (Expenses) | -3.96 | -1.33 | -4.27 | -2.02 | -2.29 | 2.85 |
EBT Excluding Unusual Items | 1,011 | 793.18 | 1,178 | 1,114 | 749.19 | 383.77 |
Impairment of Goodwill | -21.51 | -21.51 | 1.32 | -0.87 | -10.86 | - |
Gain (Loss) on Sale of Investments | -6.44 | -8.13 | -19.36 | -35.22 | -1.39 | 35.97 |
Gain (Loss) on Sale of Assets | -16.11 | -13.54 | -4.03 | -8.85 | -16.57 | -8.37 |
Asset Writedown | -91.1 | -39.11 | -0.13 | - | -5.54 | - |
Other Unusual Items | 17.92 | 19.72 | 25.26 | 35.03 | 29.92 | 38.53 |
Pretax Income | 893.7 | 730.6 | 1,181 | 1,104 | 744.74 | 449.9 |
Income Tax Expense | 170.81 | 123.53 | 149.27 | 182.85 | 110.59 | 70.01 |
Earnings From Continuing Operations | 722.89 | 607.07 | 1,031 | 920.97 | 634.15 | 379.89 |
Minority Interest in Earnings | -0.02 | -0.97 | 1.88 | 0.2 | -0.25 | 0.7 |
Net Income | 722.87 | 606.1 | 1,033 | 921.17 | 633.9 | 380.58 |
Net Income to Common | 722.87 | 606.1 | 1,033 | 921.17 | 633.9 | 380.58 |
Net Income Growth | 3.66% | -41.34% | 12.17% | 45.32% | 66.56% | 60.05% |
Shares Outstanding (Basic) | 883 | 891 | 891 | 830 | 823 | 810 |
Shares Outstanding (Diluted) | 883 | 891 | 891 | 830 | 834 | 810 |
Shares Change (YoY) | -2.06% | 0.07% | 7.33% | -0.50% | 3.00% | 2.16% |
EPS (Basic) | 0.82 | 0.68 | 1.16 | 1.11 | 0.77 | 0.47 |
EPS (Diluted) | 0.82 | 0.68 | 1.16 | 1.11 | 0.76 | 0.47 |
EPS Growth | 5.83% | -41.38% | 4.50% | 46.05% | 61.70% | 56.67% |
Free Cash Flow | 1,100 | 102.69 | 430.88 | 511.99 | 97.64 | 84.67 |
Free Cash Flow Per Share | 1.25 | 0.12 | 0.48 | 0.62 | 0.12 | 0.10 |
Dividend Per Share | 0.500 | 0.300 | 0.500 | 0.400 | 0.250 | 0.200 |
Dividend Growth | - | -40.00% | 25.00% | 60.00% | 25.00% | - |
Gross Margin | 33.12% | 30.80% | 36.19% | 33.47% | 32.41% | 36.13% |
Operating Margin | 18.01% | 13.86% | 19.96% | 18.84% | 17.87% | 17.63% |
Profit Margin | 13.50% | 11.74% | 18.71% | 16.92% | 15.60% | 14.38% |
Free Cash Flow Margin | 20.53% | 1.99% | 7.80% | 9.40% | 2.40% | 3.20% |
EBITDA | 1,372 | 1,109 | 1,479 | 1,369 | 1,017 | 718.9 |
EBITDA Margin | 25.62% | 21.50% | 26.77% | 25.13% | 25.04% | 27.16% |
D&A For EBITDA | 407.52 | 394.04 | 376.06 | 342.67 | 291.37 | 252.31 |
EBIT | 964.58 | 715.31 | 1,103 | 1,026 | 725.97 | 466.58 |
EBIT Margin | 18.01% | 13.86% | 19.96% | 18.84% | 17.87% | 17.63% |
Effective Tax Rate | 19.11% | 16.91% | 12.64% | 16.56% | 14.85% | 15.56% |
Revenue as Reported | 5,356 | 5,161 | 5,523 | 5,445 | 4,063 | 2,647 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.